目的 了解BCR/ABL阴性B系急性淋巴细胞白血病(B-ALL)患儿IKZF1基因拷贝数异常情况,并分析IKZF1基因拷贝数异常与该部分患儿预后的相关性。方法 应用多重连接探针扩增(MLPA)技术检测180例初诊BCR/ABL阴性B-ALL患儿IKZF1基因拷贝数异常情况。根据有无IKZF1基因缺失将其分成两组:IKZF1缺失组和IKZF1正常组。回顾性分析IKZF1拷贝数缺失与BCR/ABL阴性B-ALL患儿预后的关系。结果 180例患儿中共有27例(15.0%)患儿发生了IKZF1缺失,其中IKZF1基因8个外显子全部缺失者4例,单纯1号外显子缺失者17例,4~7号外显子缺失者3例,2~7号外显子缺失者3例。IKZF1缺失组患儿初诊时白细胞水平及流式MRD-高危组患儿的比例明显高于IKZF1正常组;IKZF1缺失组患儿多发生在无特殊融合基因异常的BCR/ABL阴性患儿,且IKZF1基因缺失患儿易伴随出现11、8、5、7、21号等染色体的异常。Kaplan-Meier法分析显示,IKZF1缺失组无病生存率(DFS)明显低于IKZF1正常组(0.740±0.096 vs 0.905±0.034,P=0.002)。Cox法分析显示在排除了年龄、性别、初始WBC、初诊时脑脊液状态、泼尼松松试验反应情况、染色体核型后,IKZF1缺失仍不利于患儿的DFS(P<0.05)。结论 部分BCR/ABL阴性B-ALL患儿存在IKZF1缺失,IKZF1缺失为BCR/ABL阴性B-ALL患儿DFS的独立危险因素。
Abstract
Objective To identify IKZF1 gene copy number abnormalities in BCR/ABL-negative B-lineage acute lymphoblastic leukemia (B-ALL) in children, and to investigate the association between such abnormalities and prognosis. Methods Multiplex ligation-dependent probe amplification (MLPA) was applied to detect IKZF1 gene copy number abnormalities in 180 children diagnosed with BCR/ABL-negative B-ALL. These children were classified into IKZF1 deletion group and IKZF1 normal group according to the presence or absence of IKZF1 gene deletion. The association between IKZF1 copy number abnormalities and prognosis of children with BCR/ABL-negative B-ALL was analyzed retrospectively. Results Among 180 children, 27 (15.0%) had IKZF1 deletion; among the 27 children, 4 had complete deletions of 8 exons of IKZF1 gene, 17 had deletion of exon 1, 3 had deletions of exons 4-7, and 3 children had deletions of exons 2-7. Compared with those in the IKZF1 normal group, children in the IKZF1 deletion group had higher white blood cell (WBC) count and percentage of individuals with high risk of minimal residual disease at the first visit. IKZF1 deletions often occurred in BCR/ABL-negative children with no special fusion gene abnormalities. They were frequently accompanied by abnormalities in chromosomes 11, 8, 5, 7, and 21. The analysis with Kaplan-Meier method showed that disease-free survival (DFS) in the IKZF1 deletion group was significantly lower than that in the IKZF1 normal group (0.740±0.096 vs 0.905±0.034; P=0.002). Cox analysis showed that after exclusion of sex, age, initial WBC count, cerebrospinal fluid state at the first visit, prednisone response, and chromosome karyotype, IKZF1 deletion still affected the children's DFS (P<0.05). Conclusions Some children with BCR/ABL-negative B-ALL have IKZF1 deletion, and IKZF1 deletion is an independent risk factor for DFS in children with BCR/ABL-negative B-ALL.
关键词
IKZF1 /
BCR/ABL阴性 /
β系急性淋巴细胞白血病 /
儿童
Key words
IKZF1 /
BCR/ABL-negative /
B-lineage acute lymphoblastic leukemia /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Ribera J, Morgades M, Zamora L, et al. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols[J]. Cancer, 2015, 121(21): 3809-3817.
[2] Olsson L, Johansson B. Ikaros and leukaemia[J]. Br J Haematol, 2015, 169(4): 479-491.
[3] Georgopoulos K, Moore DD, Derfler B. Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment[J]. Science, 1992, 258(5083): 808-812.
[4] Medina KL, Pongubala JM, Reddy KL, et al. Assembling a gene regulatory network for specification of the B cell fate[J]. Dev Cell, 2004, 7(4): 607-617.
[5] Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)[J]. Blood, 2009, 114(10): 2159-2167.
[6] Medeiros BC. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia[J]. N Engl J Med, 2009, 360(17): 1787.
[7] Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study[J]. Lancet Oncol, 2009, 10(2): 125-134.
[8] Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros[J]. Nature, 2008, 453(7191): 110-114.
[9] Ofverholm I, Tran AN, Heyman M, et al. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols[J]. Leukemia, 2013, 27(9): 1936-1939.
[10] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 第3版. 北京: 科学出版社, 2007: 19-23.
[11] Gao C, Zhao XX, Li WJ, et a1. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients[J]. Am J Hematol, 2012, 87(11): 1022-7.
[12] 刘晓明, 邹尧, 王慧君, 等. CCLG-2008方案治疗标危中危儿童急性淋巴细胞白血病中期随访结[J]. 中华儿科杂志, 2014, 52(6): 449-454.
[13] Dörge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol[J]. Haematologica, 2013, 98(3): 428-432.
[14] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 第3版. 北京: 科学出版社, 2007: 131-132.
[15] Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report[J]. J Clin Oncol, 2009, 27(31): 5202-5207.
[16] van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL[J]. Blood, 2014, 123(11): 1691-1698.
[17] Vitanza NA, Zaky W, Blum R, et al. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance[J]. Pediatr Blood Cancer, 2014, 61(10): 1779-1785.
基金
科技部重大专项新药平台创制(2011ZX09302-007-04);天津市科技支撑计划急性淋巴细胞白血病的预后分层和个体化治疗策略(12ZCDZSY18100);国家科技支撑计划(2007BAI04B03);自然科学基金面上项目(81470339);国家自然科学基金(81170470)。
PDF(1197 KB)
